Phase 1 trial of BI-1206 as a single agent to evaluate the PK/safety profile and in combination with rituximab in patients with Non-Hodgkin's Lymphoma (mantle cell lymphoma, marginal zone lymphoma, and follicular lymphoma)
Latest Information Update: 08 Mar 2024
At a glance
- Drugs BI 1206 (Primary) ; Rituximab (Primary)
- Indications Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- Sponsors CASI Pharmaceuticals
- 05 Mar 2024 Interim Results (n=8) presented in the CASI Pharmaceuticals Media Release.
- 17 May 2023 According to a CASI Pharmaceuticals media release, enrollment is ongoing in the second cohort.
- 07 Sep 2022 According to a CASI Pharmaceuticals media release, first patient has been dosed at Henan Cancer Hospital.